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Summary
Objective: It has been suggested that oxidized low-density lipoprotein (ox-LDL) has some roles in progression of osteoarthritis. The purpose of
this study is to investigate whether ox-LDL binding to lectin-like ox-LDL receptor 1 (LOX-1) enhances monocyte chemoattractant protein 1
(MCP-1) expression in cultured human articular chondrocytes (HACs).
Method: The time course and dose response of MCP-1 mRNA expression and MCP-1 protein release into medium following ox-LDL stimu-
lation were investigated using quantitative Real time PCR (deltaedelta Ct method) and enzyme-linked immunosorbent assay (ELISA), respec-
tively. To examine the receptor speciﬁcity of ox-LDL action, HACs were preincubated with anti-human LOX-1 monoclonal antibody (TS92).
Results: A time-course study revealed that MCP-1 mRNA expression increased 5.09 0.86 fold 12 h after ox-LDL stimulation compared to
time-0. ox-LDL stimulation increased MCP-1 protein level in conditioned medium in a time-dependent manner. Increased MCP-1 level was
evident 6 h after stimulation, reaching 830 91 pg/ml at 24 h (33 8 pg/ml at time-0). Dose responses of MCP-1 expression were also evident
in mRNA and protein levels. Pretreatment with TS92 markedly suppressed these stimulating effects of ox-LDL, although that with non-speciﬁc
IgG did not. Native LDL did not affect MCP-1 expression.
Conclusion: Our results suggest that ox-LDL enhances MCP-1 expression in HACs and supports the hypothesis that ox-LDL is involved in
cartilage degeneration.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Chemokines were originally identiﬁed by their chemotactic
activity for inﬂammatory cells1,2. Besides the implicated in-
volvement of the chemokine/chemokine receptor system
in the pathogenesis of inﬂammatory joint diseases3e5, ac-
cumulating evidence has indicated involvement of the sys-
tem in cartilage degeneration in osteoarthritis5e9, that is
chondrocytes produce the chemokines7 and express their
receptors8, whose interaction induces matrix metalloprotei-
nase (MMP)-1, 3, 13 and N-acetyl-b-D-glucosaminidase in
chondrocytes, inhibits proteoglycan synthesis by chondro-
cytes and enhances proteoglycan release from cartilage8,9.
These ﬁndings strongly suggest that this system plays a key
role in the cartilage degradation, possibly acting in an auto-
crine/paracrine manner.
Recently, it has been shown that oxidized low-density
lipoprotein (ox-LDL) uptake through lectin-like ox-LDL
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271is involved in endothelial activation and dysfunction in athe-
rogenesis10e12. Interestingly, expression of LOX-1 and as-
sociation with ox-LDL in chondrocytes were noted in
zymosan-induced arthritis rats13. We recently demonstrated
in vitro that ox-LDL binding to LOX-1 increases production
of intracellular reactive oxygen species (ROS), resulting in
activation of nuclear factor-kappaB (NF-kB)14. However,
functional consequences caused by the ox-LDL-induced
NF-kB activation have not been investigated.
It is known that ox-LDL increases monocyte chemoattrac-
tant protein 1 (MCP-1) expression in macrophages15 and
endothelial cells16, and that ox-LDL-induced MCP-1 expres-
sion in endothelial cells plays an important role in monocyte
transmigration into the subendothelial space16,17. The
purpose of this study was to investigate whether ox-LDL
binding to LOX-1 increases MCP-1 expression in cultured
human articular chondrocytes (HACs).Materials and methodsHAC CULTURESHAC culture was performed using commercially available cryopreserved
human normal chondrocytes according to the manufacturer’s instruction
(NHAC-kn, Cambrex Corp., East Rutherford, NJ, USA). After the cells had
been thawed in a 37C water bath, resuspended chondrocytes were seeded
at a density of 1 104/cm2 in growth culture medium (CGM BulletKit,
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iﬁed 5%CO2 incubator. Chondrocytes cultured in themedia were expanded in
two passages. We ﬁrst conﬁrmed that the cells used maintained properties of
chondrocytes after the cell expansion. Reverse transcription-polymerase
chain reaction (RT-PCR) and Real time PCR showed that the cultured
HACs without any stimulation constitutively expressed mRNA of both type II
collagen and aggrecan gene (data not shown). After reaching 70% conﬂuence
in monolayers, cells were cultured in the serum-free culture medium for
12e24 h and then stimulated with various agents in the serum-free medium.PREPARATION OF NATIVE LDL (n-LDL) and ox-LDLHuman LDL (density 1.019e1.063) was isolated from fresh plasma by ultra-
centrifugation as described previously10. LDL was oxidized at a protein con-
centration of 3 mg/ml by exposure to 7.5 mM CuSO4 for 20 h at 37
C.
Oxidation was monitored by measuring the amount of thiobarbituric acid-
reactive substances (10.7 nmol/mg protein) produced, and the increased
mobility on agarose gel electrophoresis, due to increased negative charge,
was compared with that of n-LDL (relative electrophoretic mobility was 3.25)10.PREPARATION OF ANTI-HUMAN LOX-1 MONOCLONAL
ANTIBODYBrieﬂy, lysate of cells expressing human LOX-1 was immunized to the
zenomouse18, and hybridoma producing anti-human LOX-1 monoclonal an-
tibody (TS92, which was called JTX92 in the past) was obtained according to
the conventional method to prepare monoclonal antibody. TS92 was puriﬁed
using protein A from serum-free medium of the hybridoma. The purity of the
antibody was veriﬁed by SDS-PAGE. Speciﬁcity and blocking ability of the
antibody against human LOX-1 were conﬁrmed by western blot and suppres-
sion of DiI-labeled ox-LDL uptake by LOX-1, respectively (data not shown).
This monoclonal antibody has been used in some experimental studies to
block ox-LDL binding to human LOX-1 and to show presence of human
LOX-1 in immunohistochemistry11,12,19e21.RT-PCR FOR LOX-1 mRNATotal RNA (1 mg) extracted from cultured HACs using Isogen (Nippon
Gene, Tokyo, Japan) was reverse transcribed using the OneStep RT-PCR
kit (Qiagen Japan, Tokyo, Japan). Reverse transcribed material (1.5 mL)
was ampliﬁed with Taq DNA polymerase (Bex, Tokyo, Japan) using primer
pairs speciﬁc to human LOX-1 (sense primer, 50-GGGGTACCCACCTACAT
TATGCAGC-30; antisense primer, 50-CCGCTCGAGCGGCCTGGTTG
CAAGCCTATAATC-30). The LOX-1 PCR products were 834 bp long,
respectively. For PCR ampliﬁcation of LOX-1, 30 cycles of 94C for 45 s,
53C for 45 s, and 72C for 60 s were used. In the same experiments, bovine
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was ampliﬁed with
equal efﬁciency as a relative internal reference. A primer pair for human
GAPDH was used (sense primer, 50-CTGCCGTCTAGAAAAACC-30; anti-
sense primer, 50-CCAAATTCGTTGTCATACC-30). The PCR product was
200 bp long. For GAPDH PCR ampliﬁcation, 30 cycles of 94C for 45 s,
53C for 45 s, and 72C for 60 s were used. The ampliﬁed samples were
visualized on 1.5% agarose gels using ethidium bromide.RNA EXTRACTION AND REAL TIME PCR ANALYSISCells were seeded at 1 105 cells/well in a 24-well plate and were al-
lowed to grow to 70% conﬂuence. All experiments were set up in triplicate
per same lot, and two different lots were used in this analysis.
Cell pellets were resuspended in 350 ml of RNeasy lysis buffer from the
RNeasy kit (Qiagen Inc., Valencia, CA, USA) and homogenized through
Qiashredder columns (Qiagen). RNA extraction was performed through
RNeasy columns according to manufacturer’s instructions. Extracted RNA
was eluted with 30 ml of diethylpyrocarbonate (DEPC) water. Single strand
cDNA was prepared from total RNA using random primer under standard con-
ditions with the high capacity cDNA reverse transcription kit (Applied Biosys-
tems, Foster City, CA, USA). The cDNA from each sample was diluted and
used for quantiﬁcation of MCP-1 and b-actin expression. Quantitative Real
time PCR with total cDNA was performed using Perfect Real time Premix
Ex-Taq (TAKARA BIO, Inc., Shiga, Japan) and following primer/probe sets
(listed 50 to 30 in the order of forward primer, probe, reverse primer): b-actin,
GGTCATCACCATTGGCAATG, CGGTTCCGCTGCCCTGAGGC, CCA
CAGGACTCCATGCCC; MCP-1, AGTGTCCCAAAGAAGCTGTGA, TCAA
GACCATTGTGGCCAAGGAGAT, CCTGAACCCACTTCTGCTTG. The
primer sets were designed to span exons to distinguish cDNA from genomic
DNA products. Probes were dual labeled with FAM and TAMRA (all primers
and probes were purchased from Sigma Genosys, Tokyo, Japan). The PCR
ampliﬁcations were performed with the 7100 Real Time PCR System (Applied
Biosystems, Foster City, CA, USA) at 95C for 5 min followed by 35 cycles of95C, 30 s; 60C, 30 s; and 72C, 30 s. Quantiﬁcation of gene expression was
based on the cycle threshold (Ct) value for each sample. Delta Ct was calcu-
lated as (gene of interest Ct) (b-actin Ct) using Sequence detector (Applied
Biosystems) and Microsoft Excel (Microsoft corp., Redmond, WA, USA). The
relative quantity of MCP-1 mRNA expressions was calculated by deltaedelta
Ct calculation as 2((treated sample delta Ct)(control sample delta Ct)). The ampliﬁcation
efﬁciencies of the target and the endogenous reference were conﬁrmed to be
approximately equal by observing that the plot of cDNA dilution vs delta Ct is
close to zero (<0.05). All experiments included negative controls consisting
of no cDNA for each primer pair.MCP-1 PROTEIN QUANTIFICATIONChondrocytes were seeded at a density of 2 105/ml in 12-well culture
plates and cultured for 5 days, reaching 70% conﬂuence in monolayers.
All experiments were set up in duplicate per same lot, and ﬁve different
lots were used in this analysis.
After incubation of the chondrocytes under the indicated conditions, the
conditioned medium was collected and centrifuged at 14,000 g for 5 min.
The MCP-1 protein level (pg/ml) was measured in the supernatant using
a human MCP-1 enzyme-linked immunosorbent assay (ELISA) kit (sandwich
method, Human MCP-1 Biotrak ELISA system, GE Healthcare UK Ltd.,
Buckinghamshire, UK) according to the manufacturer’s instruction. The
absorbance at 450 nm was measured within 10 min of addition of a reac-
tion-stopping reagent using a microplate reader (TEACAN SPECTRA
Micro-Plate Reader 539-67021, MTX Lab System Inc., Vienna, VA, USA).STATISTICAL ANALYSISResults are presented as means standard deviation (SD). Analyses of
variance, Scheffe’s tests, and un-paired Student’s t tests were used for statis-
tical assessments. A level of P< 0.05 was considered statistically signiﬁcant.ResultsLOX-1 mRNA EXPRESSION IN CULTURED HACsPrevious studies had shown that LOX-1, one of the re-
ceptors for oxidized LDL, is expressed in cultured rat22
and bovine14 articular chondrocytes. To conﬁrm LOX-1 ex-
pression in cultured HACs, changes in LOX-1 mRNA ex-
pression by ox-LDL and interleukin 1b (IL-1b) stimulation
were investigated by RT-PCR. A time-course study re-
vealed that basal level of LOX-1 mRNA expressed constitu-
tively and that by addition of 0.1 ng/ml IL-1b and 50 mg/ml
ox-LDL it reached a peak after 6 and 12 h, respectively
(data not shown).INCREASE IN MCP-1 mRNA EXPRESSION IN
CULTURED HACs BY ox-LDLAfter the HACs were washed with serum-free medium
three times, they were stimulated with 50 pg/ml IL-1b,
50 mg/ml ox-LDL, or 50 mg/ml n-LDL, and the time course
of MCP-1 mRNA expression was investigated by Real
time PCR. To examine the receptor speciﬁcity of ox-LDL
action, HACs were pretreated with 40 mg/ml anti-human
LOX-1 monoclonal antibody (TS92) for 30 min and then
stimulated with 50 mg/ml ox-LDL. We tried some concentra-
tions of TS92 in preliminary experiments to block LOX-1
and noted that 40 mg/ml TS92 provided consistent results
in complete suppression of ox-LDL-induced MCP-1 expres-
sion. ox-LDL increased MCP-1 mRNA expression in HACs.
Twelve hours after stimulation MCP-1 mRNA expression
reached a peak and the mean increase in MCP-1 mRNA
expression was estimated to be 5.09 0.86 fold (n¼ 3)
greater than time-0. Pretreatment of HACs with 40 mg/ml
TS92 for 30 min signiﬁcantly suppressed the increase in
MCP-1 mRNA expression induced by ox-LDL, although
that with non-speciﬁc IgG (human IgG, Equitech-Bio, Inc.,
Kerrville, TX, USA) did not [Fig. 1(A)].
Fig. 1. Time and dose effects of ox-LDL on MCP-1 mRNA expression. HACs were incubated with 50 g/ml IL-1b, 50 mg/ml ox-LDL, or 50 mg/ml
n-LDL, and MCP-1 mRNA expression was investigated by Real time PCR at the indicated times (A). HACs were incubated with the indicated
concentration of IL-1b, n-LDL or ox-LDL for 12 h, and MCP-1 mRNA expression was investigated by Real time PCR (B). Cells preincubated
with 40 mg/ml anti-human LOX-1 mAb (TS92) or non-speciﬁc IgG for 30 min were also stimulated with ox-LDL. Relative quantity of MCP-1
mRNA was calculated by the deltaedelta Ct method. Error bars indicate SDs (n¼ 3).
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mRNA expression was then investigated. HACs were incu-
bated with IL-1b (0, 10, 50, and 100 pg/ml), n-LDL (0, 10,
50, and 100 mg/ml) or ox-LDL (0, 10, 50, and 100 mg/ml)
for 12 h, and MCP-1 mRNA expression was investigated
by Real time PCR. HACs were pretreated with 40 mg/ml
TS92 for 30 min and then stimulated with ox-LDL (0, 10,
50, and 100 mg/ml). IL-1b and ox-LDL increased MCP-1
mRNA expression in a dose-dependent manner. n-LDL
did not signiﬁcantly affect MCP-1 mRNA expression. The
mean increase in MCP-1 mRNA expression was estimated
to be 1.91 0.32, 5.19 0.67 and 11.6 0.72 fold greater
than control for cells, when stimulated with 10, 50 and
100 mg/ml ox-LDL, respectively. Pretreatment of HACs
with TS92 signiﬁcantly suppressed the increase [Fig. 1(B)].INCREASES IN MCP-1 PROTEIN LEVEL INDUCED
BY ox-LDL IN CONDITIONED MEDIUMTo examine whether ox-LDL stimulates MCP-1 produc-
tion by HACs, MCP-1 levels in conditioned medium weredetermined by ELISA. First, the time-dependent effects of
ox-LDL on MCP-1 production were observed in HACs
incubated with 50 pg/ml IL-1b, 50 mg/ml ox-LDL, or 50 mg/
ml n-LDL. IL-1b stimulation increased MCP-1 production
by chondrocytes, reaching a mean concentration
1803 62 pg/ml 24 h after stimulation. ox-LDL stimulation
also increased MCP-1 level in conditioned medium in
a time-dependent manner. Increased MCP-1 level was
evident 6 h after stimulation with ox-LDL, reaching
830 71 pg/ml at 24 h. Pretreatment of HACs with TS92
signiﬁcantly suppressed the increase in MCP-1 protein level
by ox-LDL stimulation although that with non-speciﬁc IgG
did not [Fig. 2(A)].
Next, the dose dependence of MCP-1 production was in-
vestigated after 24 h of stimulation with IL-1b (10, 50, and
100 pg/ml), n-LDL (10, 50, and 100 mg/ml) or ox-LDL (10,
50, and 100 mg/ml). IL-1b and ox-LDL dose-dependently in-
creased MCP-1 protein level. The mean increase in MCP-1
level was estimated to be 7.5 0.92, 11.5 2.22 and
10.4 1.75 fold greater than control with stimulation with
10, 50 and 100 mg/ml ox-LDL, respectively. Pretreatment
Fig. 2. Time and dose effects of ox-LDL on MCP-1 protein level. MCP-1 protein level was determined by ELISA of conditioned medium. Time
dependent increases in MCP-1 level were observed when cells were incubated with 50 pg/ml IL-1b or 50 mg/ml ox-LDL (A). HACs were
incubated with the indicated concentration of IL-1b, n-LDL or ox-LDL for 24 h (B). Cells preincubated with anti-human LOX-1 mAb (TS92)
or non-speciﬁc IgG for 30 min were also stimulated with ox-LDL. Error bars indicate SDs (n¼ 5).
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MCP-1 level by ox-LDL stimulation [Fig. 2(B)].Discussion
Our data indicated that ox-LDL binding to LOX-1 en-
hanced MCP-1 expression in HACs. Increased MCP-1
mRNA expression and protein level in conditioned
medium were evident 6 h after stimulation with ox-LDL
and continued after 24 h, suggesting that MCP-1 upregu-
lation by ox-LDL may have both a primary effect due to
ox-LDL binding to LOX-1 and a secondary effect through
enhancement of LOX-1 expression due to its ligand ox-
LDL11,12,14,22.
In the doseeresponse experiments, MCP-1 level reached
a peak with ox-LDL stimulation at 50 mg/ml, while at 100 mg/
ml of ox-LDL, the stimulation of MCP-1 level showed a de-
creasing trend, although expression of MCP-1 mRNA
showed an signiﬁcant increasing trend at both ox-LDL
doses. This could be explained by a cytotoxic effect of
high-dose ox-LDL. Nakagawa et al. reported that ox-LDLreduced chondrocyte viability through suppression of the
PI3 kinase/Akt pathway22. We previously showed that
ox-LDL reduces glycosaminoglycan synthesis with the
decrease in cell viability23. Reduction in MCP-1 level with
high-dose ox-LDL may therefore be attributable to the
reduced chondrocyte viability.
In a previous in vitro study, we demonstrated ox-LDL-
induced ROS results in the NF-kB activation in chondro-
cytes14. It is likely that one of functional consequences of
the ox-LDL-induced NF-kB activation in chondrocytes is en-
hancement of MCP-1 expression, because the NF-kB is
known as a nuclear transcription factor for chemokine ex-
pression24e26. Activation of mitogen-activated protein ki-
nase (MAPK) may be another candidate of the signaling
pathway involved in the ox-LDL-mediated MCP-1 expres-
sion. Actually, it has been demonstrated that activation of
MAPK may play a critical role in signal transduction in ox-
LDL-mediated MCP-1 expression in endothelial cells16.
Interestingly, Pulai et al. have recently shown that ﬁbronec-
tin-fragment stimulation results in activation of MAPK in
chondrocytes, which further trigger NF-kB activation, regu-
lating MCP-1 expression27.
275Osteoarthritis and Cartilage Vol. 17, No. 2In conclusion, we indicated in this study that ox-LDL en-
hances MCP-1 expression in cultured HACs. ox-LDL may
play a signiﬁcant role in progression of cartilage degenera-
tion in osteoarthritis.
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